Clinical Trials for GSK1120212

2 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCPHI1333
09/18/2013
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination with GSK2141795
TreatmentVICCMEL1263
01/08/2013
Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.